Interviews

David Mitchell, PharmD, MBA, senior pharmacist manager and assistant clinical professor at UC Davis, addresses how health systems are overcoming financial, operational, and access challenges for patients with rare diseases.

The availability of retail pharmacies throughout the country have changed the health system in terms of accessibility and treatment, explains Mark Riggle, PharmD.

Patient-Centered Oncology Care (PCOC) conference co-chairs Kathy Oubre, MS, and Davey Daniel, MD, explain how the event unites experts to explore evolving oncology care and patient-centered strategies.

Laxmi Patel outlines how Medicaid reforms could raise bad debt, urging providers to strengthen financial counseling, assistance, and price transparency.

Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.

It's important to enhance MG treatment outcomes with strong provider-patient relationships and ongoing monitoring, explain Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD.

Laxmi Patel explains how Medicaid reforms could increase uncompensated care and the burden on hospitals, and how technology can help automate workflows.

The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression.

Research reveals that patients with both rheumatoid arthritis and MASH cirrhosis face significantly higher cardiovascular risks.

New findings reveal sotatercept's significant benefits for right ventricular function and tricuspid regurgitation in pulmonary arterial hypertension.

Laxmi Patel discusses proposed Medicaid reforms in HR 1, including work rules, coverage limits, and state-level risks for vulnerable populations.

Elena Losina, PhD, codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital, discusses the cost-effectiveness of varying weight loss interventions.

On this episode of Managed Care Cast, experts discuss behavioral health services, stigma reduction, and the 4 dimensions of recovery.

Refat Rasul Srejon, MPH, found that Affordable Care Act (ACA) dependent coverage had mixed effects on young adults’ substance-related emergency department (ED) visits.

The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.

The subcutaneous dose had comparable efficacy to intravenous dosing while enhancing patient convenience in non–small cell lung cancer, explains Nicolas Girard, MD, PhD.

John Byrnes of Banner|Aetna emphasizes collaboration and data-driven strategies to enhance care quality, access, and affordability in health care.

Cilta-cel demonstrates superior efficacy and durability in treating high-risk myeloma, balancing effectiveness with safety concerns for patients.

Byoung Chul Cho, MD, PhD, of the Yonsei University College of Medicine, discussed outcomes in the COCOON trial of an enhanced dermatologic regimen with amivantamab-lazertinib treatment.

A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.

Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous formulation, explained Sun Lim Min, MD, PhD.

New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations.

Disparities in lung cancer biomarker testing show barriers that delay diagnosis and treatment for lower-income patients, according to Sandip P. Patel, MD.

Personalized testing is preferred for patients with NSCLC with mutations, but there are challenges to implementing this testing, said Yang Xia, MD, PhD.

Efren Flores, MD, of Harvard Medical School and Massachusetts General Hospital, discussed the findings of a subanalysis of the Screen ASSIST tobacco cessation clinical trial.

Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).

Oranus Mohammadi, MD, outlines how antibody-drug conjugates are transforming breast cancer treatment across subtypes and discusses her approach to sequencing high-cost targeted therapies within payer and clinical practice constraints.

Matias Sanchez, MD, a hematologist-oncologist at University of Illinois Health, discussed the latest advancements in value-based multiple myeloma care, including minimal residual disease strategies and innovative targeted therapies.